↓ Skip to main content

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)

Overview of attention for article published in BMC Medicine, August 2022
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
20 Mendeley